FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2331191539> ?p ?o ?g. }

• W2331191539 endingPage "A979" @default.
• W2331191539 startingPage "A979.1" @default.
• W2331191539 abstract "<h3>Background</h3> As known, glucocorticoid-induced osteoporosis is the most common form of osteoporosis. The most pressing issue remains the prevention of osteoporosis in patients with prolonged therapy by glucocorticosteroid. The role of Zoledronic acid (ZOL) for glucocorticoid-induced osteoporosis in patients with inflammatory joints disease remains debatable. <h3>Objectives</h3> we aimed to evaluate the effects of Zoledronic acid for glucocorticoid-induced osteoporosis in patients with inflammatory joints disease. <h3>Methods</h3> 20 patients (mean age – 57,20±4,46 years) with inflammatory joints disease were enrolled. All patients were women and received glucocorticoid during more than 5 years (mean duration of treatment – 3,20±0,46 years). Women had osteoporosis documented by either a lumbar spine T-score ≤–2.5 or lumbar spine T-score ≤–1.5 with 2 mild or 1 moderate prevalent vertebral fracture. 10 (50%) patients received the standard treatment and Zoledronic acid 5 mg infusion once a year (study group), while 20 (50%) (control group) – received only the standard treatment for 3 years. Visual Analog Scale (VAS), <i>bone mineral density (BMD)</i> were performed in all patients at baseline and at the end of the study. <h3>Results</h3> VAS and <i>BMD</i> did not differ significantly between the groups. After 3 years of treatment with Zoledronic acid the incidence of symptoms, including arthralgia were significantly lower in the study in comparison of control groups (P = 0.05). The increase in BMD was greater in the study group than in the control group (P = 0.01). During 3 years among patients in the control group 30% have compression fractures in compare with study group (P = 0.05). <h3>Conclusions</h3> Zoledronic acid is effective and safe for patients with glucocorticoid-induced osteoporosis in patients with inflammatory joints disease. Its administration may provide benefits for the reduction of hospitalizations and mortality in its population. <h3>Disclosure of Interest</h3> None Declared" @default.
• W2331191539 created "2016-06-24" @default.
• W2331191539 creator A5084916635 @default.
• W2331191539 creator A5086196552 @default.
• W2331191539 creator A5086246391 @default.
• W2331191539 date "2013-06-01" @default.
• W2331191539 modified "2023-09-28" @default.
• W2331191539 title "AB0620 Effects of zoledronic acid for glucocorticoid-induced osteoporosis in patients with inflammatory joints disease" @default.
• W2331191539 doi "https://doi.org/10.1136/annrheumdis-2013-eular.2942" @default.
• W2331191539 hasPublicationYear "2013" @default.
• W2331191539 type Work @default.
• W2331191539 sameAs 2331191539 @default.
• W2331191539 citedByCount "0" @default.
• W2331191539 crossrefType "journal-article" @default.
• W2331191539 hasAuthorship W2331191539A5084916635 @default.
• W2331191539 hasAuthorship W2331191539A5086196552 @default.
• W2331191539 hasAuthorship W2331191539A5086246391 @default.
• W2331191539 hasConcept C126322002 @default.
• W2331191539 hasConcept C141071460 @default.
• W2331191539 hasConcept C14184104 @default.
• W2331191539 hasConcept C198451711 @default.
• W2331191539 hasConcept C2776326535 @default.
• W2331191539 hasConcept C2776541429 @default.
• W2331191539 hasConcept C2776886416 @default.
• W2331191539 hasConcept C2777251235 @default.
• W2331191539 hasConcept C2780841215 @default.
• W2331191539 hasConcept C71924100 @default.
• W2331191539 hasConceptScore W2331191539C126322002 @default.
• W2331191539 hasConceptScore W2331191539C141071460 @default.
• W2331191539 hasConceptScore W2331191539C14184104 @default.
• W2331191539 hasConceptScore W2331191539C198451711 @default.
• W2331191539 hasConceptScore W2331191539C2776326535 @default.
• W2331191539 hasConceptScore W2331191539C2776541429 @default.
• W2331191539 hasConceptScore W2331191539C2776886416 @default.
• W2331191539 hasConceptScore W2331191539C2777251235 @default.
• W2331191539 hasConceptScore W2331191539C2780841215 @default.
• W2331191539 hasConceptScore W2331191539C71924100 @default.
• W2331191539 hasIssue "Suppl 3" @default.
• W2331191539 hasLocation W23311915391 @default.
• W2331191539 hasOpenAccess W2331191539 @default.
• W2331191539 hasPrimaryLocation W23311915391 @default.
• W2331191539 hasRelatedWork W1974859234 @default.
• W2331191539 hasRelatedWork W1983172052 @default.
• W2331191539 hasRelatedWork W2024045126 @default.
• W2331191539 hasRelatedWork W2090647941 @default.
• W2331191539 hasRelatedWork W2150247306 @default.
• W2331191539 hasRelatedWork W2223937660 @default.
• W2331191539 hasRelatedWork W2331191539 @default.
• W2331191539 hasRelatedWork W3035708703 @default.
• W2331191539 hasRelatedWork W337812723 @default.
• W2331191539 hasRelatedWork W4242077342 @default.
• W2331191539 hasVolume "72" @default.
• W2331191539 isParatext "false" @default.
• W2331191539 isRetracted "false" @default.
• W2331191539 magId "2331191539" @default.
• W2331191539 workType "article" @default.